Daxor Corp.

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.

DAXOR Corporation is an innovative medical instrumentation and biotechnology company. DAXOR designed and developed the BVA-100 Blood Volume Analyzer. It is the first instrument approved by the FDA to provide rapid direct measurement of a patient's true blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility.   The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. It is the first FDA-approved instrument to provide rapid direct measurement of a patient's blood volume.

Daxor's Blood Volume Technology Featured at Scientific Session Oak Ridge, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America (HFSA) which brings together the world's leading experts in heart failure at the Huntington Convention Center in Cleveland, Ohio from October 6-9, 2023.

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor C orporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) has awarded the Company a $305K Phase I Small Business Innovative Research (SBIR) grant to support the development of the Sepsis FLO (Sepsis Fluid Optimizer), a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.

Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.

Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Net Assets Increases to $30.4 Million From $29.0 Million Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six-months ended June 30, 2023. The unaudited financials reported included an increase in revenue of 20.64 percent in the Company's diagnostic test kits compared to the same period from 2022 represents strong strides in the commercialization of its BVA-100® Blood Volume Analyzer through a combination of the purchase and leasing of capital equipment, the launch of Daxor's ezBVA Lab service, and the opening of eight new commercial and academic accounts during the past six- months.

Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023

Researchers Call for Larger Clinical Trial Citing Outcomes from Study Oak Ridge, TN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a research letter in the Journal of the American College of Cardiology – Heart Failure reporting on the successful results of a pilot 31 patient randomized control trial (RCT) conducted by the Duke Clinical Research Institute utilizing Daxor's BVA-100 diagnostic to measure clinician assessment accuracy and the impact of optimizing decongestion therapy for heart failure patients with the diagnostic. The study results showed that all patients had marked volume derangements, but that in over 68% of the cases care teams did not correctly diagnose the volume state of the patient by clinical exam when compared to BVA.

JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®

Volume and Pressure Measures are Complementary, Not Interchangeable Oak Ridge, TN, July 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a new research letter in the Journal of the American College of C ardiology – Heart Failure validating the benefits of the Company's BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. The study, titled “Discordant Pressure-Volume Trends During CardioMEMS Monitoring,” evaluated the correlation of pressure-volume profiles over two time periods in a series of heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor's blood volume analysis (BVA) diagnostic.

JACC-HF Study Compares Daxor's BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

Oak Ridge, TN, July 05, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the United States Defense Health Agency (DHA) has awarded the Company a $1.1 million sequential Phase II Small Business Innovative Research (SBIR) contract to add the capability of electronic medical record (EMR) integration to its small, portable, highly accurate, battery-powered blood volume analyzer.

Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer

Oak Ridge, TN, June 22, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Maxim Group LLC (“Maxim”), as Representative of several Underwriters of its previously announced secondary public offering have partially exercised their option to purchase an additional 54,339 Option Shares of Daxor's Class A common stock (the “Over-Allotment Option”) at a public price of $9.75 per share.

Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering

Oak Ridge, TN, June 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Michael Feldschuh, CEO and President has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest. The conference is being held virtually on June 20 - 22, 2023.

Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference

Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share. Gross proceeds from the offering are approximately $4.0 million before deducting underwriting discounts, commissions, and estimated offering expenses.

Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering

Oak Ridge, TN, May 22, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 per share. Gross proceeds from the offering are expected to be approximately $4.0 million before deducting underwriting discounts, commissions, and estimated offering expenses.

Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering

Daxor Corp.'s stock DXR, -6.06% tumbled 22% premarket Monday, after the company announced plans to issue stock. The company, which is registered as a closed-end investment company to raise the funds for its medical device and biotech operations, announced the plan in a filing with the Securities and Exchange Commission on Friday, without disclosing the exact number of shares to be issued.

Daxor stock tumbles 22% premarket after announcing plans to issue stock

Oak Ridge, TN, May 19, 2023 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announces that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Daxor. In addition, Daxor intends to grant the underwriter in the offering a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts, and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Daxor Corporation Announces Proposed Underwritten Public Offering

Daxor's BVA Technology Shown to Provide Unique and Individualized Data for Patient Management Oak Ridge, TN, May 18, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor's BVA-100 blood test in heart failure patients published in the European Society of Cardiology Heart Failure . The results of the study demonstrated Daxor's blood volume analysis (BVA) provides unique and individualized data that is critical for targeting heart failure therapy and is predictive of clinical outcomes.

New Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

Study Demonstrates BVA Provides More Accurate Congestion Measurement in Challenging Patient Populations Oak Ridge, TN, April 20, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of the Company's BVA-100 blood test in optimizing individualized therapy for advanced heart failure patients. Data were presented at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions, which brought together the world's leading experts in heart and lung transplant held at the Colorado Convention Center, from April 19-22, in Denver, CO.

New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

Expert Users to Present “Blood Volume Analysis – Breaking the Heart Failure Cycle” Oak Ridge, TN, April 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring'23 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 20-22, 2023. The CV Transforum conference unites cardiovascular thought leaders from across the country to transform cardiovascular care together with leading industry innovators.

Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring'23 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic (BVA-100®)

Company to Showcase Three New Research Studies Utilizing Blood Volume Analysis Oak Ridge, TN, April 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions, which brings together the world's leading experts in heart and lung transplant being held at the Colorado Convention Center, from April 19-22, in Denver, CO. The Company will host a booth and new data will be featured highlighting the applicability of blood volume analysis (BVA) titled, “Differences in Pressure-Volume Relati onship Between Obese and Non-Obese Patients with Advanced Heart Failure” (Poster #116.531), “Relationship Between Blood Volume Measures and Cardiopulmonary Exercise Testing Performance in Advanced Heart Failure” (Poster #117.532), and “Differences in Cardi opulmonary Exercise Performance Between True Anemia and Hemodilution in Patients with Advanced Heart Failure”(Poster #118.537) All posters will be presented in the Mile High Ballroom.

Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Oak Ridge, TN, March 27, 2023 (GLOBE NEWSWIRE) --   Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company's BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) sales, while providing additional validation for the use of BVA in the clinical setting.

Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients

Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA

New Study Confirms Daxor's BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients

Daxor Corporation (NASDAQ:DXR ) Q4 2022 Results Conference Call March 2, 2023 9:00 AM ET Company Participants Scott Gordon - President, Core IR Michael Feldschuh - CEO Robert Michel - CFO Conference Call Participants Anthony Vendetti - Maxim Group Evan Greenberg - Legend Cap Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Daxor Corp. Fiscal Year 2022 Financial Results and Corporate Update Conference call.

Daxor Corporation (DXR) Q4 2022 Earnings Call Transcript

Conference Call to be held today at 9:00 AM EST

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management.

Daxor Corporation Appoints Linda Cooper, Vice President Project Management

Oak Ridge, TN, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be presenting at the Society for Critical Care Medicine (SCCM) 2023 Critical Care Congress at the Moscone Center In San Francisco, CA from January 21 through the 24, 2023.

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress

Oak Ridge, TN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. In addition, the underwriter has partially exercised its over-allotment option, purchasing an additional 10,523 shares of common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Daxor from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Daxor, are expected to be $2.1 million. All of the shares of common stock sold in the offering were offered by Daxor.

Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option

Oak Ridge, TN, Nov. 15, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share. The gross proceeds to Daxor from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Daxor, are expected to be $2.0 million. In addition, Daxor has granted the underwriter in the offering a 45-day option to purchase up to an additional 10,527 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The offering is expected to close on November 17, 2022, subject to customary closing conditions.

News for Daxor Corp. Stock (DXR)